1. Home
  2. KSCP vs KLRS Comparison

KSCP vs KLRS Comparison

Compare KSCP & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knightscope Inc.

KSCP

Knightscope Inc.

HOLD

Current Price

$4.03

Market Cap

46.4M

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$8.65

Market Cap

46.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSCP
KLRS
Founded
2013
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.4M
46.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
KSCP
KLRS
Price
$4.03
$8.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$16.67
$20.67
AVG Volume (30 Days)
385.9K
49.4K
Earning Date
03-30-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,610,000.00
N/A
Revenue This Year
$9.63
N/A
Revenue Next Year
$31.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.50
N/A
52 Week Low
$2.45
$2.14
52 Week High
$10.14
$12.90

Technical Indicators

Market Signals
Indicator
KSCP
KLRS
Relative Strength Index (RSI) 45.69 51.63
Support Level $3.45 $8.80
Resistance Level $3.98 $10.28
Average True Range (ATR) 0.28 0.76
MACD 0.03 -0.04
Stochastic Oscillator 63.21 43.86

Price Performance

Historical Comparison
KSCP
KLRS

About KSCP Knightscope Inc.

Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: